Saturday, May 07, 2016

The upcoming case on the "on-sale" bar involving The Medicines Company and Angiomax

From within a post at Statnews on the Angiomax case:

Meanwhile, in its own court filing in support of The Medicines Company, the BIO industry trade group wrote the panel decision “would apply to any contract in which a patent holder uses a CMO [contract manufacturer organization] to assist in producing a product made by a patentable process. Such an interpretation of the on-sale bar discourages use of CMOs and, accordingly, promotes an inefficient and costly method of production of valuable pharmaceuticals.”


A prior post on IPBiz:


Post a Comment

<< Home